Merck & Company Inc (MRK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Merck & Company Inc (MRK) has a cash flow conversion efficiency ratio of 0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.92 Billion) by net assets ($45.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MRK net asset quality score to measure how much of total assets are equity-financed.
Merck & Company Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Merck & Company Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MRK cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Merck & Company Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merck & Company Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Netflix Inc
NASDAQ:NFLX
|
0.079x |
|
Cisco Systems Inc
NASDAQ:CSCO
|
0.038x |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
0.325x |
|
Agricultural Bank of China Ltd Class A
SHG:601288
|
0.359x |
|
Novartis AG
MX:NVSN
|
0.094x |
|
Royal Bank of Canada
TO:RY
|
-0.106x |
|
Morgan Stanley
SA:MSBR34
|
-0.030x |
|
AstraZeneca PLC
MX:AZNN
|
0.048x |
Annual Cash Flow Conversion Efficiency for Merck & Company Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Merck & Company Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see Merck & Company Inc (MRK) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.66 Billion | $16.47 Billion | 0.313x | -32.44% |
| 2024-12-31 | $46.37 Billion | $21.47 Billion | 0.463x | +33.96% |
| 2023-12-31 | $37.63 Billion | $13.01 Billion | 0.346x | -16.64% |
| 2022-12-31 | $46.06 Billion | $19.09 Billion | 0.415x | +12.42% |
| 2021-12-31 | $38.26 Billion | $14.11 Billion | 0.369x | -8.62% |
| 2020-12-31 | $25.40 Billion | $10.25 Billion | 0.404x | -21.92% |
| 2019-12-31 | $26.00 Billion | $13.44 Billion | 0.517x | +27.22% |
| 2018-12-31 | $26.88 Billion | $10.92 Billion | 0.406x | +117.86% |
| 2017-12-31 | $34.57 Billion | $6.45 Billion | 0.186x | -27.55% |
| 2016-12-31 | $40.31 Billion | $10.38 Billion | 0.257x | -7.22% |
| 2015-12-31 | $44.77 Billion | $12.42 Billion | 0.277x | +72.23% |
| 2014-12-31 | $48.79 Billion | $7.86 Billion | 0.161x | -27.67% |
| 2013-12-31 | $52.33 Billion | $11.65 Billion | 0.223x | +23.26% |
| 2012-12-31 | $55.46 Billion | $10.02 Billion | 0.181x | -16.91% |
| 2011-12-31 | $56.94 Billion | $12.38 Billion | 0.217x | +14.15% |
| 2010-12-31 | $56.80 Billion | $10.82 Billion | 0.191x | +245.33% |
| 2009-12-31 | $61.48 Billion | $3.39 Billion | 0.055x | -82.23% |
| 2008-12-31 | $21.17 Billion | $6.57 Billion | 0.310x | -8.66% |
| 2007-12-31 | $20.59 Billion | $7.00 Billion | 0.340x | +0.32% |
| 2006-12-31 | $19.97 Billion | $6.77 Billion | 0.339x | -9.22% |
| 2005-12-31 | $20.38 Billion | $7.61 Billion | 0.373x | -16.46% |
| 2004-12-31 | $19.70 Billion | $8.80 Billion | 0.447x | -11.70% |
| 2003-12-31 | $19.49 Billion | $9.86 Billion | 0.506x | +22.82% |
| 2002-12-31 | $23.13 Billion | $9.53 Billion | 0.412x | -5.23% |
| 2001-12-31 | $20.89 Billion | $9.08 Billion | 0.435x | +12.27% |
| 2000-12-31 | $19.85 Billion | $7.69 Billion | 0.387x | +5.49% |
| 1999-12-31 | $16.70 Billion | $6.13 Billion | 0.367x | +13.71% |
| 1998-12-31 | $16.51 Billion | $5.33 Billion | 0.323x | -29.68% |
| 1997-12-31 | $13.76 Billion | $6.32 Billion | 0.459x | +20.77% |
| 1996-12-31 | $14.28 Billion | $5.43 Billion | 0.380x | +81.01% |
| 1995-12-31 | $14.02 Billion | $2.94 Billion | 0.210x | -37.37% |
| 1994-12-31 | $12.35 Billion | $4.14 Billion | 0.335x | +22.80% |
| 1993-12-31 | $11.17 Billion | $3.05 Billion | 0.273x | -38.63% |
| 1992-12-31 | $5.63 Billion | $2.50 Billion | 0.445x | +0.71% |
| 1991-12-31 | $5.51 Billion | $2.43 Billion | 0.442x | -5.81% |
| 1990-12-31 | $4.38 Billion | $2.06 Billion | 0.469x | +36.89% |
| 1989-12-31 | $4.03 Billion | $1.38 Billion | 0.343x | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more